NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Read more about NPC Submits Comments to CMS on Proposed Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program
Unmet Need in the IRA Drug Price Negotiation Program Read more about Unmet Need in the IRA Drug Price Negotiation Program
Maximum Fair Price Effectuation and Independent Pharmacies: Risks to Patient Access and Choice Read more about Maximum Fair Price Effectuation and Independent Pharmacies: Risks to Patient Access and Choice
The Impact of the Inflation Reduction Act’s Drug Pricing Negotiation Program on Incentives for Clinical Development of New Drugs Read more about The Impact of the Inflation Reduction Act’s Drug Pricing Negotiation Program on Incentives for Clinical Development of New Drugs
New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives Read more about New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives
NPC Submits Comments to CMS Regarding the Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for CY 2026 Read more about NPC Submits Comments to CMS Regarding the Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for CY 2026
NPC Submits Comments to CMS Regarding the Physician Fee Schedule (PFS) Proposed Rule for CY 2026 Read more about NPC Submits Comments to CMS Regarding the Physician Fee Schedule (PFS) Proposed Rule for CY 2026
Inflation Reduction Act Impact on Pharmaceutical Investment: Insights From Investor Interviews Read more about Inflation Reduction Act Impact on Pharmaceutical Investment: Insights From Investor Interviews
77% of Investors Say IRA's "Pill Penalty" Disincentivizes Small Molecule Investments Read more about 77% of Investors Say IRA's "Pill Penalty" Disincentivizes Small Molecule Investments
Research Finds That Post-Approval Cancer Trials Fell After IRA Passage, With Disproportionate Impact on Small Molecule Drugs Read more about Research Finds That Post-Approval Cancer Trials Fell After IRA Passage, With Disproportionate Impact on Small Molecule Drugs